SCHEMBL19670663

SCHEMBL19670663

CCN1CCCN(C(=O)Nc2ccccn2)c2nc(-c3ccnc(C(F)(F)F)c3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 4/20 0.40
▸ TRPV1 Q8NER1 1/20 0.39
▸ TRPV3 Q8NET8 1/20 0.36
▸ PDE4B Q07343 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ MET P08581 1/20 0.34
▸ TGFBR1 P36897 1/20 0.34
▸ NPC1 O15118 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ CHRNA10 Q9GZZ6 1/20 0.34
▸ CHRNA9 Q9UGM1 1/20 0.34
▸ NR3C2 P08235 1/20 0.33
▸ PIK3C3 Q8NEB9 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19670530 0.91 FAAH (0.41) TRPV3PDE4BGRIN2BHTR2AHTR2C
SCHEMBL19670433 0.90 ALOX15 (0.36) FGFR4TRPV3PDE4BGRIN2B
SCHEMBL19670394 0.90 FAAH (0.34) FGFR4TRPV3PDE4BGRIN2BFAAH
SCHEMBL19670591 0.88 FGFR4 (0.42) FGFR4FAAHCHRNA7CHRNA10CHRNA9
SCHEMBL19670453 0.85 HTR2C (0.36) TRPV3PDE4BGRIN2BCYP1A2HTR2A
SCHEMBL12654669 0.84 CNR2 (0.50) FGFR4FAAH
SCHEMBL19670692 0.83 BRAF (0.38) TRPV3PDE4BCYP1A2HTR2AHTR2C
SCHEMBL19365377 0.82 FGFR4 (0.39) FGFR4PDE4BFAAH
SCHEMBL16775937 0.82 FGFR4 (0.42) FGFR4TRPV1PDE4BFAAHTGFBR1
SCHEMBL19699070 0.80 FGFR4 (0.41) FGFR4FAAHNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20190048016-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-02-14 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1754/4885TRPV1 3670/4885TRPV3 4093/4885
US-20190048016-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1926/4885TRPV1 3814/4885TRPV3 4136/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 FGFR4 1754/4885TRPV1 3670/4885TRPV3 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback